L
L&C Bio Co Ltd
KOSDAQ:290650
L&C Bio Co Ltd
KOSDAQ:290650
Price:
62 100
KRW
-0.48%
Market Cap:
1.5T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
L&C Bio Co Ltd
62100
-300 (-0.48%)
| 52 Week Range |
18 950
72 700
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
Delete Alert
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
L&C Bio Co Ltd
L&C Bio Co Ltd
| Current Assets | 141.9B |
| Cash & Short-Term Investments | 59.9B |
| Receivables | 24.7B |
| Other Current Assets | 57.3B |
| Non-Current Assets | 347.7B |
| Long-Term Investments | 30.4B |
| PP&E | 97B |
| Intangibles | 200.2B |
| Other Non-Current Assets | 20.1B |
| Current Liabilities | 136.2B |
| Accounts Payable | 9.4B |
| Short-Term Debt | 32.7B |
| Other Current Liabilities | 94.1B |
| Non-Current Liabilities | 40.3B |
| Long-Term Debt | 22.5B |
| Other Non-Current Liabilities | 17.8B |
Balance Sheet
L&C Bio Co Ltd
L&C Bio Co Ltd
Currency: KRW
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
584
|
383
|
3 119
|
12 310
|
6 962
|
4 639
|
9 472
|
6 589
|
14 949
|
18 287
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
584
|
383
|
3 119
|
12 310
|
6 962
|
4 639
|
9 472
|
6 589
|
14 949
|
18 287
|
|
| Short-Term Investments |
0
|
3 494
|
3 461
|
24 274
|
21 951
|
22 705
|
2 238
|
5 725
|
44 243
|
5 851
|
|
| Total Receivables |
3 083
|
4 353
|
5 892
|
7 418
|
10 137
|
9 306
|
13 242
|
13 553
|
19 894
|
52 049
|
|
| Accounts Receivables |
2 925
|
4 295
|
5 533
|
7 071
|
9 054
|
9 159
|
12 751
|
13 216
|
18 721
|
21 794
|
|
| Other Receivables |
158
|
58
|
359
|
347
|
1 083
|
147
|
492
|
337
|
1 174
|
30 255
|
|
| Inventory |
3 889
|
5 143
|
5 372
|
5 581
|
6 230
|
8 085
|
12 312
|
34 203
|
46 288
|
46 779
|
|
| Other Current Assets |
51
|
213
|
211
|
324
|
812
|
765
|
2 459
|
4 211
|
4 982
|
7 223
|
|
| Total Current Assets |
7 606
|
13 586
|
18 054
|
49 906
|
46 090
|
45 501
|
47 632
|
64 284
|
130 357
|
130 189
|
|
| PP&E Net |
1 109
|
1 445
|
1 447
|
4 902
|
7 287
|
9 483
|
17 895
|
53 138
|
74 655
|
97 017
|
|
| PP&E Gross |
1 109
|
1 445
|
1 447
|
4 902
|
7 287
|
9 483
|
17 895
|
53 138
|
74 655
|
97 017
|
|
| Accumulated Depreciation |
725
|
972
|
1 238
|
1 126
|
2 341
|
3 868
|
6 385
|
10 460
|
13 849
|
16 516
|
|
| Intangible Assets |
39
|
109
|
93
|
87
|
218
|
215
|
1 150
|
1 255
|
1 456
|
1 932
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2 320
|
0
|
197 307
|
|
| Note Receivable |
123
|
0
|
0
|
690
|
0
|
0
|
700
|
1 000
|
646
|
1 158
|
|
| Long-Term Investments |
108
|
151
|
289
|
0
|
9 602
|
22 433
|
36 754
|
75 768
|
47 254
|
31 373
|
|
| Other Long-Term Assets |
127
|
368
|
608
|
1 794
|
3 029
|
2 945
|
3 269
|
1 961
|
7 861
|
16 626
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2 320
|
0
|
197 307
|
|
| Total Assets |
9 111
N/A
|
15 661
+72%
|
20 490
+31%
|
57 379
+180%
|
66 226
+15%
|
80 576
+22%
|
107 401
+33%
|
199 725
+86%
|
262 230
+31%
|
475 601
+81%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
965
|
348
|
282
|
238
|
191
|
266
|
1 021
|
2 910
|
1 745
|
2 331
|
|
| Accrued Liabilities |
163
|
58
|
45
|
63
|
107
|
137
|
164
|
332
|
468
|
816
|
|
| Short-Term Debt |
450
|
0
|
200
|
0
|
0
|
0
|
0
|
9 508
|
8 247
|
31 600
|
|
| Current Portion of Long-Term Debt |
454
|
542
|
263
|
0
|
169
|
370
|
733
|
1 134
|
72 469
|
68 263
|
|
| Other Current Liabilities |
420
|
1 233
|
2 495
|
2 760
|
2 933
|
2 902
|
3 717
|
4 855
|
18 909
|
51 699
|
|
| Total Current Liabilities |
2 452
|
2 181
|
3 284
|
3 060
|
3 401
|
3 675
|
5 635
|
18 738
|
101 838
|
154 708
|
|
| Long-Term Debt |
2 234
|
2 989
|
0
|
1 000
|
1 622
|
14 663
|
6 098
|
71 303
|
1 417
|
24 038
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
1 194
|
592
|
900
|
63
|
|
| Minority Interest |
0
|
0
|
0
|
337
|
2 087
|
3 446
|
8 245
|
9 869
|
9 911
|
10 372
|
|
| Other Liabilities |
512
|
472
|
394
|
519
|
932
|
985
|
1 208
|
1 271
|
1 219
|
2 067
|
|
| Total Liabilities |
5 198
N/A
|
5 641
+9%
|
3 678
-35%
|
4 916
+34%
|
8 043
+64%
|
22 769
+183%
|
22 380
-2%
|
101 773
+355%
|
115 285
+13%
|
191 248
+66%
|
|
| Equity | |||||||||||
| Common Stock |
1 268
|
1 318
|
1 493
|
3 617
|
3 680
|
10 985
|
11 388
|
11 388
|
11 388
|
11 388
|
|
| Retained Earnings |
2 533
|
4 551
|
8 446
|
13 654
|
20 746
|
20 639
|
33 342
|
36 865
|
83 593
|
222 197
|
|
| Additional Paid In Capital |
112
|
3 761
|
6 858
|
35 172
|
35 500
|
30 659
|
43 875
|
51 988
|
51 994
|
51 990
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
1 038
|
2 201
|
337
|
1 738
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
4 310
|
6 358
|
6 358
|
3 890
|
3 873
|
|
| Other Equity |
0
|
390
|
17
|
19
|
1 742
|
166
|
1 735
|
1 868
|
3 523
|
4 389
|
|
| Total Equity |
3 913
N/A
|
10 020
+156%
|
16 813
+68%
|
52 463
+212%
|
58 183
+11%
|
57 806
-1%
|
85 021
+47%
|
97 952
+15%
|
146 945
+50%
|
284 353
+94%
|
|
| Total Liabilities & Equity |
9 111
N/A
|
15 661
+72%
|
20 490
+31%
|
57 379
+180%
|
66 226
+15%
|
80 576
+22%
|
107 401
+33%
|
199 725
+86%
|
262 230
+31%
|
475 601
+81%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
15
|
16
|
18
|
22
|
22
|
22
|
23
|
23
|
23
|
23
|
|
Switch to:
Switch to:
See Also
Discover More
